Patients with HIV showed lower cases of steatotic liver disease when switched to ViiV Healthcare’s Dovato compared to ...
In the draft guidance published on 23 February, the FDA specifically discusses genome editing and RNA-based therapies that are highly specific, personalised therapies. Credit: H_Ko/Shutterstock.com ...
In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema ...
Gossamer Bio has reported topline data from the Phase III PROSERA study evaluating seralutinib in patients with PAH.
Compass will now seek approval for COMP360 in TRD, which could become the first classic psychedelic to gain the FDA’s ...
The North Midlands CRDC has recruited its first patient, representing the UK’s initial participation in a clinical trial of ...
Prasad and Makary disagree that some may believe this move to just one pivotal trial shows the FDA relaxing its standards.
Roche's Gazyva could become the first drug to gain approval in membranous nephropathy, pending regulatory decisions from the ...
Clinical trials are facing new and evolving challenges as costs increase and approval timelines remain lengthy. Modernisation ...
CStone Pharmaceuticals' IND application has received FDA clearance, enabling the company to initiate a Phase II trial of its trispecific antibody CS2009.
Another of Pfizer’s Braftovi regimens has shown benefit in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation.
Evommune’s potential Dupixent competitor has met its primary endpoint in a Phase IIa atopic dermatitis (AD) trial, achieving a 33% reduction in Eczema Area and Severity Index (EASI).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results